Assessing how Hepatitis B affects Inflammatory Bowel Disease
The Impact of Hepatitis B Virus Infection on the Clinical Course of Inflammatory Bowel Disease in Egyptian Patients
This study is trying to see how having hepatitis B affects the symptoms and treatment outcomes for people with inflammatory bowel disease in Egypt.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 162 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, Gharbyea) |
| Trial ID | NCT06881238 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the influence of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) among Egyptian patients. Researchers will compare various aspects of IBD, including its extent, location, severity, and behavior, between patients with and without HBV infection. Data will be collected through patient history, clinical examinations, laboratory tests, abdominal ultrasounds, and endoscopic evaluations. The study focuses on understanding the relationship between these two conditions to improve patient management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with inflammatory bowel disease.
Not a fit: Patients under 18 years old or those unwilling to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of how HBV impacts IBD, leading to better treatment strategies for affected patients.
How similar studies have performed: While the specific relationship between HBV and IBD is less explored, similar observational studies have provided insights into the interactions between viral infections and autoimmune diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients older than 18 years. * Patients with IBD are diagnosed by clinical, radiological, endoscopic, and histological criteria. Exclusion Criteria: * Patients aged \< 18 years * Unwilling to participate in our study
Where this trial is running
Tanta, Gharbyea
- Tanta University Hospitals — Tanta, Gharbyea, Egypt (Recruiting)
Study contacts
- Study coordinator: Rania M Elkafoury, MD
- Email: rania.elkafoury@med.tanta.edu.eg
- Phone: +201004672358
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.